Global Monoclonal Antibodies Market 2016-2020

July 20, 2016
SKU:
IRTNTR9857
This market research report identifies players like AbbVie, F. Hoffmann-La Roche, Johnson & Johnson, Amgen, Merck, and BMS to be the key vendors in the global mAbs market. This research report also presents a detailed segmentation of the market by application (oncology, autoimmune and inflammatory diseases, respiratory diseases, ophthalmology, and others) and by geography (the Americas, APAC, and EMEA).

Overview of the global monoclonal antibodies (mAbs) market

Technavio’s market research analyst predicts the global monoclonal antibodies (mAbs) market to grow at a CAGR of around 10% by 2020. Antibodies are increasingly becoming the preferred choice to treat several disorders such as respiratory diseases, oncology, and inflammatory diseases. The use of antibody-dependent cytotoxicity (ADC), including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing significantly. The rising application of these antibodies in drug development increases revenue generation in the mAbs market, contributing to the overall market growth. DCs are highly effective cytotoxic drugs associated with mAbs, and are considered potent and efficient in treating diseases, including cancers and hematological malignancies. Vendors are inclined towards the development of novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU), which will positively aid in the growth of this market during the predicted period.

Several mAb vendors are shifting toward developing economies, such as India and China, as these countries offer large population groups as customers and clinical trial subjects. Factors such as lenient regulatory guidelines, low manufacturing expenses, skilled man force, and restricted market competition help vendors to decrease the overall development costs of therapeutics and increases their profit. The rising gross domestic products (GDP) and awareness among the middle class have increased the acceptance of mAbs in countries like Brazil, Russia, India, and China (BRIC). Moreover, the favorable regulatory reforms in these emerging markets will further boost the growth prospects for mAbs vendors and will result in their increased revenue.

Competitive landscape and key vendors

The market is diverse with the presence of several global and regional players. The key vendors dominate this market and compete with the local players on the basis of cost, prices, technology, and product differentiation. The vast growth opportunities in the market will encourage the entry of new players. However, their entry will be restricted due to presence of highly stringent guidelines to manufacture mAbs. F. Hoffmann-La Roche was the largest vendor in the market in 2015 and occupied more than 35% of the total market revenue. It has retained its dominant position in the market through its wide range of monoclonal antibodies offerings, including Avastin, Perjeta, MabThera/Rituxan, Kadcyla, Actemra/RoActemra, Herceptin, and Lucentis.

Leading vendors in the market are -

  • AbbVie
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Amgen
  • Merck
  • BMS

Other prominent vendors in the mAbs market include AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, and UCB.

Segmentation by application and analysis of the mAbs market

  • Oncology
  • Autoimmune and inflammatory diseases
  • Respiratory diseases
  • Ophthalmology

Oncology is the largest application segment in the mAbs market and is anticipated to occupy more than 49% of the overall market share by 2020. Avastin and Herceptin the top-selling oncology mAbs in the market. An expected increase in the number of incidences of cancer and the introduction of immune checkpoint inhibitors will contribute to the growth of this segment. F Hoffmann-La Roche has a dominant position in the global oncology mAb segment and is focusing towards expanding the indications of existing mAbs and gaining the approvals of novel products. 

Geographical segmentation and analysis of the mAbs market

  • Americas
  • APAC
  • EMEA

APAC will be the fastest-growing region in the mAbs market and is likely to grow at a CAGR of around 17% by 2020. Much of the region’s growth can be attributed to the rising occurrence of diseases and healthcare investments provided by the respective governments and increased out-of-pocket expenditure by individuals. Moreover, the rising number of initiatives undertaken by major vendors to assist patients in the APAC countries and recent launches of new products are significant contributors to the high sales of sales mAbs in this region.

 Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global mAbs market?
  • What are the key market trends impacting the growth of the global mAbs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global mAbs market?
  • What are the market opportunities and threats faced by the vendors in the global mAbs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global mAbs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

Monoclonal antibodies (mAbs) are the proteins produced by the bone marrow’s B-cells in the immune system. These proteins attach to antigens and are then trashed by phagocytes. mAbs are monospecific because they are the clones of a single parent cell and comprise identical immune cells. They are complex proteins and have a high molecular weight. These proteins are classified as chimeric, humanized, and fully human. They are frequently used in therapies such as antibody-directed enzyme prodrug therapy and radioimmunotherapy, and drug development.

The report, global monoclonal antibodies market, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.